ARLG at ECCMID

Support your ARLG colleagues who will be presenting at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands from April 13-16, 2019.

Date/ Time Session Title Presenter (Chair or Moderator noted) Topic (if presenter) Place
Saturday, April 13 13:30 – 14:30 Antibacterial activity of unusual combinations Barry Kreiswirth Multifactorial treatment approaches targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae Arena 2
Saturday, April 13 14:45 – 15:45 Clinical Trials with recently approved or late- stage development antibiotics Thomas Holland An efficacy analysis by lesion size of iclaprim versus vancomcin in patients with acute bacterial skin and skin structure infections: pooled phase III REVIVE trials Arena 5
Saturday, April 13 14:45 – 15:45 Beta-lactamase inhibitors:  the “second generation” meets the “first generation” problems Robert Bonomo Imipenem-relebactam efficiently inhibits D179 variants of the KPC-2 beta-lactamase Arena 2
Saturday, April 13
10:00 – 12:00
Management of chronic bone and joint infections Robin Patel (Chair) Hall D
Sunday, April 14 11:00 – 12:00 Pathogenetic profiling to fight antimicrobial resistance Robert Bonomo (Chair) Hall K
Sunday, April 14 14:45 – 15:45 Antibodies in the flight against multidrug-resistant Gram-negative bacterial infection Robert Bonomo (Chair) Hall H
Sunday, April 14
11:00 – 12:00
Possible impact of new immunomodulators on infection and infection management David van Duin (Chair) Hall B
Sunday, April 14
14:45 – 15:45
US experiences Bettina C. Fries Antibody-mediated killing of multidrug-resistant Gram-negative bacteria: what’s the future? Hall H
Monday, April 15 07:30 – 8:30 How to use Point-of-Care tests in microbiology? European vs. Robin Patel (Chair) Robin Patel (Rochester, United States) Hall J
Monday, April 15 16:00 – 18:00 Phage therapy’s coming of age: Progress towards the application of bacteriophages in the treatment of infectious diseases Robin Patel (Chair) Hall J
Tuesday, April 16 08:45 – 10:45 MRSA, VRE and beyond Cesar Arias (chair) Hall H
Tuesday, April 16 11:00 – 12:00 Recent Clinical Trials Vance Fowler Exebacase (Lysin CF-301) Improved clinical responder rates in methicillin-resistant Staphylococcus aureus bacteraemia including endocarditis compared to standard of care antibiotics alone in a first-in patient phase 2 study Hall N
Tuesday, April 16
11:00 – 12:00
Infection in immunocompromised hosts David van Duin (Chair) Hall J
Tuesday, April 16
12:15 – 13:15
Networks for Clinical Research – no other way David van Duin (Moderators) Arena 4
Tuesday, April 16
12:15 – 13:15
Networks for Clinical Research – no other way Sarah Doernberg ARLG in the USA Arena 4
Tuesday, April 16
13:30 – 15:30
Interventions to reduce morbidity and mortality of bloodstream infection Thomas Holland Patients’ experiences with Staphylococcus aureus and Gram-negative rod bloodstream infections: a qualitative study to inform development of a quality of life measure Hall N
Tuesday,April 16 13:30 – 15:30 Bacterial resistance: evolution, plasmids and fitness Barry Kreiswirth Processes driving the evolution of antibiotic resistance Hall E

 

Michael Woodworth, MD, MSc, receives the Southern Society for Clinical Investigation Research Scholar Award

Congratulations to Michael Woodworth, MD, MSc, for being selected as a recipient of the Southern Society for Clinical Investigation (SSCI) Research Scholar Award. This award provides funding for physician-scientists with innovative research projects related to internal medicine and its subspecialties. Dr. Woodworth will use the award to provide additional project funding for the ARLG ongoing pilot clinical trial of fecal transplantation for MDRO eradication in renal transplant patients.

 

Two ARLG PI-Initiated, Laboratory-Based Trials Reached Database Lock

ARLG Principal Investigators Ritu Banerjee, MD, PhD of Vanderbilt University and Audrey Schuetz, MD, MPH, D (ABMM) of Mayo Clinic have successfully led the RAPIDS-GN and DISK trials, respectively, to completion.

The primary objective of RAPIDS-GN is to evaluate the impact of rapid identification and antimicrobial susceptibility testing (AST) on the time to first antibiotic modification in the first 72 hours after randomization. RAPIDS-GN enrolled 500 subjects in two sites over 1 year. Database lock occurred in March 2019. Dr. Banerjee expects to present the preliminary results at the American Society for Microbiology (ASM) Microbe meeting in June 2019.

The primary objective of the DISK trial is to evaluate the performance of a rapid disk diffusion test performed using positive blood culture broth (BCB) as the inoculum, read at 16-18 hours of incubation. The project enrolled 500 subjects across five sites over 7 months. Database lock occurred in February 2019. Dr. Schuetz expects to present preliminary results at the Clinical & Laboratory Standards Institute (CLSI) meeting in June 2019.

Congratulations to both ARLG PIs and study sites on this accomplishment. We are looking forward to the results for answering these important questions.

MDRO Network Team Members Travel to Sites to Connect, Train, and Support Quality Worldwide

Members of the ARLG Multi-Drug Resistant Organism (MDRO) Network coordinating team are visiting sites around the world to assess training success in several regions and find ways to enhance partnerships and practices within the MDRO Network.

This Network is a global community of professionals with a common mission to participate in clinical trials that: 1) provide observational data to aid in the design of randomized clinical trials on therapeutics and diagnostics for MDRO infections; 2) develop new diagnostic and treatment paradigms; and 3) inform clinical practice that will improve the care and outcomes of patients with antimicrobial resistance around the world.

The MDRO Network has 57 sites in 11 countries. Under the oversight of MDRO Principal Investigator, David van Duin, MD, PhD, and in collaboration with regional leaders Cesar Arias, MD, PhD, David Paterson, MBBS, PhD, Minggui Wang, MD, Lead Clinical Research Associates (LCRAs) David Souto and Beth Evans conducted these site visits in accordance with the National Institutes of Health (NIH) regulatory compliance requirements. Souto traveled to Colombia and Argentina while Evans visited sites in China, Singapore, and Australia.

  • Partner with the Regional Coordinator Center (RCC) coordinators to ensure and document that regional oversight is successfully established and fulfill the funding source (NIH) regulatory and quality compliance requirements;
  • Determine the need or desire for additional training at the site, Regional Coordinating Center (RCC), or Regional Central Laboratory (RCL) level;
  • Ensure that region-specific developed processes and tools meet regional needs and are implemented successfully;
  • Ensure that RCCs and RCLs are implementing Good Clinical Practices and Good Documentation Practices successfully;
  • Discuss ongoing and future bi-directional collaborations;
  • Share lessons learned, discuss efficiencies, and solicit feedback on how ARLG/MDRO can better support our collaborators.

Evans stated, “Being able to connect with these regional centers and sites in person, gives us valuable information and shows us, that despite cultural and language differences, everyone involved contributes their best work to help with combating the global threat of antimicrobial resistance.”

While visiting these RCCs, RCLs, and sites, the ARLG/MDRO team members toured, reviewed, and observed various study related components, facilities, and processes. On occasion, the Lead CRA team member supported the RCC’s onsite efforts, and offered recommendations and re-trainings.  These visits highlight the collaborative, bi-directional features of the Network and lay the groundwork for future trials.

MDRO coordinators also hosted regional training sessions during the site visits. These trainings gave members of the ARLG/MDRO coordinating team the opportunity to meet site study teams and other Network members, as well as, provide face-to-face information about study design, procedures, implementation, and clinical research best practices.

“These site visits have given us a great opportunity to get to know the people conducting studies around the world,” said Souto. “Having the opportunity to explain why this work is important and get to know the people at the regional centers has helped us to ensure dedicated engagement, as well as standardization, consistency and quality throughout the MDRO Network.”

Clinical Case Challenge on Diagnostics and AMR

We call on you to support the “Clinical Case Challenge” – an international challenge highlighting the value of in vitro diagnostics in the fight against AMR.

This challenge invites medical students, trainees, physicians and others worldwide to submit their case studies on this important healthcare topic, thereby increasing open access cases for medical education.

Many medical schools have gaps in clinical diagnostics and antimicrobial resistance (AMR) content. A challenge is proposed to solicit clinical diagnostic and AMR clinical cases through a global call for participation. Clinical diagnostics are tests to aid clinical management and/or guide treatment decisions. The purpose of the challenge is to encourage medical students, trainees, physicians, and others to collect or write clinical cases that could be used in medical education and shared online. The challenge has two types of clinical cases: original cases written specifically for the contest and not published before; adapted cases that have been published elsewhere and tailored for medical education use.

Guidelines for submissions are described below. The final deadline for cases is May 1st, 2018.

bioMérieux is proud to be the sole sponsor of this initiative developed by the International Diagnostics Center and the London School of Hygiene and Tropical Medicine, the main organizer of this contest. Send your clinical case!

Details: http://www.seshglobal.org/Clinical-Case-Challenge

Questions: Contact the challenge coordinator at AMRcasechallenge@gmail.com

IDSA Honors 105 Distinguished Physicians, Scientists with FIDSA

IDSA congratulates the distinguished physicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.

Fellowship in IDSA honors those who have achieved professional excellence and provided significant service to the profession. “There has never been a more critical nor more exciting time for the field of infectious diseases. From an emerging outbreak of Ebola in the Congo to domestic outbreaks of measles to working tirelessly to solve the mystery of the patients before them, infectious diseases doctors are on the front lines of research and clinical care, keeping us safe from dangerous illness,” said IDSA President Paul Auwaerter, MD, MBA, FIDSA. “The individuals receiving the FIDSA designation have demonstrated that they are true leaders—in their institutions, their communities, and in the field of infectious diseases.”

Check out the individuals who were honored as Fellows of IDSA.